The Covid vaccine manufacturer Biontech announced last December the purchase of Curevac, a company in Tübingen, in good words: "The acquisition of Curevac complements Biontech's capabilities." The German Federal Cartel Office had approved the purchase. Less than five months later, this week, Biontech announced that all 700 jobs in Tübingen will be cancelled, allegedly because of overcapacity. Workers' representatives suspect that Biontech only b…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
The Covid vaccine manufacturer Biontech announced last December the purchase of Curevac, a company in Tübingen, in good words: "The acquisition of Curevac complements Biontech's capabilities." The German Federal Cartel Office had approved the purchase. Less than five months later, this week, Biontech announced that all 700 jobs in Tübingen will be cancelled, allegedly because of overcapacity. Workers' representatives suspect that Biontech only b…